U.S. health officials have confirmed a significant increase in cases of Candida auris, a drug-resistant fungus that poses a serious threat in medical environments. As of 2026, the fungus has been detected in 23 states across the country, with more than 3,100 confirmed cases reported nationwide, surpassing last year’s figures.
The states with the highest incidence are Texas and Michigan, where public health authorities have observed particularly rapid growth in infections. This trend underscores the urgent challenge health systems face in containing the spread of this resilient pathogen.
A Resistant Threat in Healthcare Facilities
Candida auris is especially concerning because it can persist on surfaces within healthcare settings, facilitating transmission among patients. The Centers for Disease Control and Prevention (CDC) highlights that the fungus primarily affects individuals who are already critically ill, particularly those relying on invasive medical devices such as breathing tubes, feeding tubes, or catheters.
Symptoms of infection often include fever, chills, low blood pressure, and rapid heart rate. While the general population faces a relatively low risk of severe illness, the danger remains highest among hospitalized patients and residents of long-term care facilities, where the fungus can spread swiftly and cause outbreaks.
The confirmed states reporting Candida auris cases include:
- Arizona
- California
- Colorado
- Connecticut
- Florida
- Georgia
- Illinois
- Indiana
- Kansas
- Louisiana
- Maryland
- Massachusetts
- Michigan
- Minnesota
- Missouri
- Nevada
- New Jersey
- New York
- North Carolina
- Ohio
- Oregon
- Tennessee
- Texas
Healthcare providers and public health officials continue to monitor the situation closely, emphasizing infection control measures to limit the spread of this formidable superbug within vulnerable populations.